Movac

Movac is New Zealand’s most experienced technology venture investor, operating from Wellington with a track record that spans multiple decades and includes participation in many of the most consequential technology exits in the country. The firm focuses on Series A and beyond, transitioning deep-tech startups from local New Zealand traction into globally competitive companies, with healthcare exposure concentrated in medical devices, AI in healthcare, and health IT.

The Movac thesis emphasizes companies that have established meaningful product traction in New Zealand or Australia and need substantial capital to scale internationally. Within healthcare the firm gravitates toward companies with credible technical or clinical differentiation rather than pure software plays, including medical device platforms, AI-driven diagnostic tools, and health IT systems serving institutional customers. The team is comfortable with the long capital deployment cycles that healthcare scale-up typically requires and brings perspective on what New Zealand companies actually need to compete internationally rather than what they need to dominate the small domestic market.

Check sizes commonly fall in the one to five million dollar range at entry, with the firm participating at Series A, Series B, and growth rounds. Follow-on capacity scales with conviction in companies that demonstrate progress on international expansion. Geographic focus is New Zealand with active engagement in trans-Tasman opportunities including Australian companies that maintain New Zealand operations or founders. The firm’s relationships with international investors are essential for portfolio companies that need to assemble syndicates beyond the relatively thin New Zealand institutional base.

The team is small relative to the firm’s deployment, with senior partners carrying significant deal load and bringing substantial New Zealand venture experience. Diligence emphasizes financial discipline, capital efficiency, and credible international expansion strategy, reflecting the realities of building global companies from a small domestic market. Decision-making is reasonably efficient for prepared founders.

For founders, Movac is the natural Series A and beyond venture choice in New Zealand for ambitious technology companies, including those in healthcare. The firm’s introductions are most valuable for downstream international fundraising, particularly with Australian and global growth investors who follow New Zealand venture activity through Movac as a primary signal. Post-investment engagement is active at board level and on strategic decisions, with partners engaging consistently on international expansion, hiring senior commercial leaders, and capital strategy. Founders building purely for the New Zealand domestic market will find the firm’s growth ambitions out of step with their plans, but for medical device, AI healthcare, and health IT founders translating New Zealand technical advantages into globally competitive companies, Movac is the most established institutional partner in the country and one of the few firms with the experience and network to support that specific transition consistently across multiple companies and decades.